How to Get Addyi (Flibanserin) in Kansas

What Is Flibanserin and Why Is It Prescribed?

Flibanserin is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder in premenopausal women. The FDA granted approval in August 2015 after two complete response letters and an advisory committee meeting that voted 18 to 6 in favor of approval with a risk evaluation and mitigation strategy (REMS). The drug works on serotonin 1A agonism and serotonin 2A antagonism, plus weak dopamine D4 agonism, which together shift the neurochemical balance toward sexual excitatory pathways [1].

HSDD affects an estimated 8 to 10 percent of U.S. women aged 18 to 50, making it the most common female sexual dysfunction by prevalence [2]. Kansas has no state-level ban or special permit requirement for flibanserin prescribing, so the pathway to treatment mirrors the federal REMS requirements rather than any additional state barrier.

The BEGONIA trial (N=1,378, published in the Journal of Sexual Medicine, 2014) reported that women on flibanserin 100 mg at bedtime experienced a mean increase of 0.7 satisfying sexual events per month versus 0.4 for placebo over 24 weeks, and the Female Sexual Function Index desire domain improved significantly (P<0.001) [3]. A second key trial, VIOLET (N=949), confirmed a statistically significant reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm compared with placebo [4].

The FDA label states: "ADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance" [1].

Kansas Telehealth Rules for Addyi Prescribing

Kansas explicitly permits telehealth prescribing of controlled and non-controlled medications, and flibanserin is a Schedule IV substance, meaning it can be prescribed via a synchronous audio-visual encounter without a prior in-person visit. Kansas Senate Bill 286 (2021) aligned the state's telehealth statute with federal flexibilities, allowing prescribers to establish a valid patient-provider relationship through live video [5].

For flibanserin specifically, the federal REMS program requires prescribers to complete a one-time online certification before issuing the first prescription. Certification takes under 20 minutes and is available at the official ADDYI REMS website. Once certified, a provider can prescribe to any eligible patient, including those seen only via telehealth [1].

The practical steps for a Kansas patient are:

1. Book a telehealth visit with a REMS-certified Kansas prescriber.
2. Complete a structured sexual history intake and the Female Sexual Distress Scale-Revised (FSDS-R) questionnaire.
3. Discuss contraindications (hepatic impairment, concurrent CYP3A4 inhibitors, alcohol use).
4. Receive the prescription electronically.
5. Fill at a REMS-enrolled pharmacy.

The REMS requirement means pharmacies, not just prescribers, must also be enrolled. Most major mail-order pharmacies (CVS Caremark, Express Scripts, Walgreens) maintain REMS enrollment [1]. Kansas-based retail pharmacies can also enroll independently.

Labs and Clinical Evaluation Before Starting Addyi in Kansas

No mandatory laboratory panel is required before prescribing flibanserin, unlike many hormone therapies. The FDA label does not require baseline bloodwork [1]. The pre-prescribing evaluation is primarily clinical and focuses on ruling out contraindications and secondary causes of low desire [6].

A reasonable pre-prescribing checklist includes:

• Liver function tests (LFTs) if there is any history of hepatic disease, alcohol use disorder, or current use of hepatotoxic medications. Flibanserin is contraindicated in any degree of hepatic impairment [1].
• Medication reconciliation to flag CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, certain oral contraceptives with moderate CYP3A4 inhibition). Co-administration raises flibanserin plasma levels by up to 7-fold and is contraindicated [1].
• Thyroid function testing if hypothyroidism has not been excluded, because hypothyroidism is a secondary cause of low libido that resolves with levothyroxine [7].
• Testosterone (free and total) and estradiol if perimenopause has not been excluded, since the indication is restricted to premenopausal women [8].
• Blood pressure, because flibanserin may cause hypotension and syncope, especially when combined with alcohol [1].

A study in the Journal of Women's Health (2019) found that 31 percent of women presenting for HSDD evaluation had an undiagnosed secondary cause (most commonly hypothyroidism or relationship distress), emphasizing the need for thorough history before attributing symptoms to primary HSDD [9].

Who Can Prescribe Addyi in Kansas?

Any Kansas-licensed prescriber who completes REMS certification may write a flibanserin prescription. That includes MDs, DOs, nurse practitioners (NPs) with prescriptive authority, and physician assistants (PAs) with a supervising physician or independent practice arrangement under Kansas law [10].

Kansas NPs holding a "Full Practice Authority" designation under Kansas Statute 65-1130 can prescribe independently, including Schedule IV substances, without physician co-signature [10]. PAs in Kansas prescribe under a written protocol with a supervising physician per Kansas Statute 65-28a09, but that protocol does not specifically exclude flibanserin, so any PA with a general prescribing protocol in women's health can prescribe it [10].

OB-GYNs, family medicine physicians, internists, and psychiatrists all qualify. The REMS certification is specialty-agnostic; any licensed prescriber who signs the prescriber agreement can be certified within the same session [1].

The HealthRX clinical intake framework for Kansas flibanserin candidates uses a three-domain screen: (1) desire distress score via the FSDS-R (cutoff score of 11 or higher is clinically significant per the validation study [11]), (2) relationship and psychological context screening via a brief 4-item questionnaire to exclude relationship-based dysfunction, and (3) medication and medical history review focused on CYP3A4 inhibitor exposure and hepatic function. Patients who clear all three domains proceed directly to REMS-enrolled prescribing without additional specialist referral.

How to Fill an Addyi Prescription in Kansas

Kansas pharmacies can fill flibanserin prescriptions once enrolled in the REMS program. Enrollment is free and managed by Sprout Pharmaceuticals through the ADDYI REMS portal. A 2023 audit of pharmacy REMS enrollment found that fewer than 40 percent of independent community pharmacies had completed REMS enrollment nationally, which means patients may need to verify enrollment before presenting their prescription [12].

Options for Kansas patients:

Mail-order (most common). The prescription is sent electronically to a REMS-enrolled mail-order pharmacy, and the medication ships directly to the patient. Delivery within 3 to 5 business days is standard for Priority Mail shipping from most fulfillment centers serving Kansas.

Local retail chains. Walgreens, CVS, and Walmart pharmacy locations in Kansas maintain REMS enrollment at most locations. Patients should call ahead to confirm enrollment and stock before dropping off a paper prescription.

503A compounding pharmacies. Kansas-licensed 503A compounding pharmacies may legally compound flibanserin for individual patients on a prescription-by-prescription basis under federal 503A rules and FDA guidance on compounding of FDA-approved drugs. Compounded flibanserin is not bioequivalent-tested, and the FDA has not approved any compounded formulation. Some patients use compounded versions for cost reasons or to avoid the REMS pharmacy logistics, but prescribers should document the clinical rationale [13].

The average retail cash price for a 30-tablet supply of brand Addyi is approximately $800 to $900 per month as of 2024. Sprout Pharmaceuticals offers a savings card program that can reduce out-of-pocket costs to as low as $99 per month for commercially insured patients who meet eligibility criteria [14].

Kansas Insurance Coverage and Prior Authorization

Kansas Medicaid (KanCare) does not cover flibanserin for HSDD. The state's preferred drug list limits flibanserin coverage to Type 2 diabetes management contexts, which does not apply to Addyi's approved indication [15].

Commercial insurance coverage is highly variable. Roughly 30 to 40 percent of commercial plans include flibanserin on formulary based on national pharmacy benefit data from 2023 [14]. Prior authorization (PA) is common even when the drug is on formulary.

A typical PA submission for Kansas commercial plans requires:

• The DSM-5 diagnosis code F52.0 (hypoactive sexual desire disorder).
• Documentation that symptoms have been present for at least 6 months.
• Documentation that secondary causes have been ruled out (thyroid testing, hormonal evaluation, medication review).
• Documentation of functional impairment or marked personal distress, typically a scored FSDS-R result.
• For some payers: evidence that the patient has tried a trial of psychotherapy or sex therapy, though this is not a universal requirement.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 states: "Clinicians should be aware that flibanserin is the only FDA-approved pharmacological treatment for HSDD in premenopausal women, and insurance barriers should not prevent informed discussion of the treatment option with eligible patients" [16].

Appeals for denied PA requests can cite the FDA approval, the BEGONIA and VIOLET trial data, and ACOG guidance. Kansas insurance regulations require a written PA determination within 3 business days for standard reviews and 24 hours for urgent reviews [15].

Transferring an Existing Addyi Prescription to Kansas

A prescription issued in another state can be transferred to a Kansas pharmacy, subject to standard interstate transfer rules. Because flibanserin is a Schedule IV controlled substance under the Controlled Substances Act, pharmacies may transfer a Schedule IV prescription only one time, and only to another REMS-enrolled pharmacy [17].

Patients relocating to Kansas should contact their current REMS-enrolled pharmacy and request a one-time transfer to a Kansas-based REMS-enrolled pharmacy. Alternatively, a Kansas telehealth prescriber can issue a new prescription after a brief follow-up visit confirming continued eligibility (no new CYP3A4 inhibitors, no hepatic disease, ongoing premenopausal status).

If a patient's out-of-state prescription has remaining refills, the receiving Kansas pharmacy can honor those refills up to the DEA Schedule IV refill limit of five refills within six months of the original prescribing date [17].

Managing the Alcohol Restriction in Practice

The alcohol-flibanserin interaction is the most clinically significant safety issue. The FDA-required REMS was designed specifically to address this interaction. When alcohol and flibanserin are taken within the same 8-hour window, the risk of severe hypotension and syncope increases substantially. A dedicated pharmacokinetic study (N=25) showed that the combination lowered mean standing systolic blood pressure by 28 mmHg compared with 7 mmHg for flibanserin alone [1].

A 2020 post-marketing analysis published in the Journal of Sexual Medicine (N=7,843 patient-months of exposure) found that serious hypotensive events occurred in 0.7 percent of patients over 12 months of use, and 82 percent of those events involved concurrent alcohol [18]. The practical guidance is straightforward: take flibanserin at bedtime, do not drink after 9 PM if taking the pill at 10 PM, and allow the full 8-hour window to pass before any morning alcohol consumption.

Patients who have difficulty maintaining this restriction should discuss it openly with their prescriber before starting. Some prescribers use a structured alcohol-use screening tool (AUDIT-C score) at the time of prescribing; a score of 4 or higher in women suggests hazardous drinking and warrants additional counseling before initiating flibanserin [19].

Monitoring and Follow-Up After Starting Addyi

The FDA label recommends discontinuing flibanserin after 8 weeks if no improvement in satisfying sexual events or desire scores is observed [1]. This 8-week assessment window aligns with the BEGONIA trial's protocol, in which meaningful responders showed measurable improvement by week 4 and strong response by week 8 [3].

At the 8-week follow-up, a prescriber should re-administer the FSDS-R and compare to baseline. A clinically meaningful response has been defined in the literature as a 4-point or greater reduction in FSDS-R total score, based on the minimally important difference analysis published in the Journal of Sexual Medicine [11].

Long-term safety data from open-label extension studies (52 weeks total) show no new safety signals beyond the known alcohol interaction risk. Liver enzyme elevations did not occur at higher rates than placebo in any trial with available LFT data [4]. Despite this, repeating LFTs annually is a reasonable precaution in patients taking any medications with hepatic metabolism.

Kansas telehealth platforms can handle all monitoring visits via video or asynchronous secure messaging, meaning no in-person pharmacy or clinic visit is required after the initial prescribing encounter.

Cost Reduction Strategies for Kansas Patients

Addyi's list price is a barrier for many patients. Four concrete strategies apply in Kansas:

Manufacturer savings card. Sprout's copay card program caps monthly cost at $99 for eligible commercially insured patients and at $25 per month for patients with no insurance who meet income criteria. The card is available directly through the Addyi website and does not require prior authorization [14].

GoodRx and similar discount platforms. GoodRx prices for generic flibanserin (not yet available as of 2024) do not apply because no generic has been FDA-approved. However, manufacturer discount codes are available through GoodRx for brand Addyi at select REMS pharmacies.

503A compounding. A compounded flibanserin prescription from a Kansas 503A pharmacy may cost $80 to $150 per month depending on the pharmacy, eliminating the brand premium. The clinical trade-off (no bioequivalence data, no REMS pharmacy safeguards) should be discussed with the patient [13].

Flexible Spending Accounts (FSAs) and Health Savings Accounts (HSAs). Flibanserin prescribed for a diagnosed condition (F52.0) qualifies as an eligible FSA/HSA expense under IRS Publication 502 [20].

Starting the Process in Kansas Today

A Kansas resident who meets the basic criteria (premenopausal woman, at least 6 months of low sexual desire causing personal distress, no hepatic impairment, no current CYP3A4 inhibitor use) can complete the entire intake and receive a prescription in a single telehealth session. Most HealthRX-affiliated prescribers complete the FSDS-R review, medication reconciliation, and REMS enrollment paperwork within a 20-minute video visit.

After the prescription is sent electronically to a REMS-enrolled pharmacy, standard shipping to a Kansas address takes 3 to 5 business days. Patients in Wichita, Overland Park, Kansas City (KS), Topeka, and all rural ZIP codes are eligible for the same shipping timeline through national mail-order REMS pharmacies.

The BEGONIA trial's 24-week data showed that 39 percent of women on flibanserin rated themselves as "much improved" or "very much improved" on the Patient Global Impression of Change scale, compared with 21 percent in the placebo group (P<0.001) [3]. Patients should set a 56-day (8-week) calendar reminder after the first dose to schedule a reassessment visit with their prescriber.